CytoMed Therapeutics Limited (GDTC)
NASDAQ: GDTC · Real-Time Price · USD
0.950
+0.050 (5.56%)
Apr 29, 2026, 12:42 PM EDT - Market open
CytoMed Therapeutics Balance Sheet
Financials in millions SGD. Fiscal year is January - December.
Millions SGD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2019 |
| Cash & Equivalents | 2.1 | 4.97 | 9 | 1.58 | 2.51 | Upgrade
|
| Short-Term Investments | - | - | - | - | 0.02 | Upgrade
|
| Cash & Short-Term Investments | 2.1 | 4.97 | 9 | 1.58 | 2.53 | Upgrade
|
| Cash Growth | -57.84% | -44.74% | 469.41% | -37.51% | 172.19% | Upgrade
|
| Accounts Receivable | 0.1 | 0.02 | - | - | - | Upgrade
|
| Other Receivables | 0.03 | 0.1 | 0.2 | 0.06 | 0.01 | Upgrade
|
| Receivables | 0.13 | 0.12 | 0.2 | 0.06 | 0.01 | Upgrade
|
| Inventory | 1.07 | 0.84 | 0.68 | 0.58 | 0.43 | Upgrade
|
| Prepaid Expenses | 0.34 | 0.04 | 0.16 | 0.05 | 0.14 | Upgrade
|
| Other Current Assets | 0.03 | 0.03 | 0.06 | 0.24 | 0.18 | Upgrade
|
| Total Current Assets | 3.66 | 6 | 10.1 | 2.49 | 3.28 | Upgrade
|
| Property, Plant & Equipment | 3.69 | 3.25 | 2.06 | 2.47 | 2.5 | Upgrade
|
| Long-Term Investments | 0.02 | 0.22 | 0.2 | 0.24 | 0.27 | Upgrade
|
| Goodwill | 0 | 0 | 0 | 0 | 0 | Upgrade
|
| Other Intangible Assets | 0.12 | 0.09 | 0.01 | 0.02 | 0.03 | Upgrade
|
| Other Long-Term Assets | 0.02 | - | - | - | - | Upgrade
|
| Total Assets | 7.98 | 10.07 | 12.37 | 5.23 | 6.08 | Upgrade
|
| Accounts Payable | 0.12 | 0.04 | 0.02 | 0.01 | 0.05 | Upgrade
|
| Accrued Expenses | 0.26 | 0.36 | 0.45 | 0.24 | 0.15 | Upgrade
|
| Short-Term Debt | - | - | - | 3.7 | 2.66 | Upgrade
|
| Current Portion of Long-Term Debt | 0.04 | 0.04 | 0.03 | 0.03 | 0.04 | Upgrade
|
| Current Portion of Leases | 0.02 | 0.01 | 0.01 | 0.01 | 0.01 | Upgrade
|
| Current Income Taxes Payable | - | - | - | 0 | - | Upgrade
|
| Current Unearned Revenue | 0.18 | 0.11 | 0.01 | 0.01 | 0.02 | Upgrade
|
| Other Current Liabilities | 0.09 | 0.05 | 0.2 | 0.16 | 0.02 | Upgrade
|
| Total Current Liabilities | 0.71 | 0.61 | 0.72 | 4.17 | 2.94 | Upgrade
|
| Long-Term Debt | 0.37 | 0.39 | 0.41 | 0.47 | 0.54 | Upgrade
|
| Long-Term Leases | 0.05 | 0.02 | - | 0.01 | 0.02 | Upgrade
|
| Total Liabilities | 1.13 | 1.02 | 1.12 | 4.64 | 3.49 | Upgrade
|
| Common Stock | 24.66 | 23.79 | 23.72 | 8.91 | 6.55 | Upgrade
|
| Retained Earnings | -18.83 | -14.85 | -12.33 | -8.2 | -5.07 | Upgrade
|
| Comprehensive Income & Other | 0.72 | 0.02 | -0.14 | -0.13 | 1.11 | Upgrade
|
| Total Common Equity | 6.54 | 8.97 | 11.25 | 0.59 | 2.59 | Upgrade
|
| Minority Interest | 0.31 | 0.08 | -0 | -0 | -0 | Upgrade
|
| Shareholders' Equity | 6.85 | 9.04 | 11.24 | 0.59 | 2.59 | Upgrade
|
| Total Liabilities & Equity | 7.98 | 10.07 | 12.37 | 5.23 | 6.08 | Upgrade
|
| Total Debt | 0.48 | 0.46 | 0.45 | 4.22 | 3.26 | Upgrade
|
| Net Cash (Debt) | 1.61 | 4.51 | 8.55 | -2.64 | -0.73 | Upgrade
|
| Net Cash Growth | -64.21% | -47.27% | - | - | - | Upgrade
|
| Net Cash Per Share | 0.14 | 0.39 | 0.80 | -0.33 | -0.11 | Upgrade
|
| Filing Date Shares Outstanding | 11.83 | 11.54 | 11.54 | 11.53 | 8.44 | Upgrade
|
| Total Common Shares Outstanding | 11.83 | 11.54 | 11.53 | 8.44 | 7.48 | Upgrade
|
| Working Capital | 2.95 | 5.39 | 9.38 | -1.67 | 0.35 | Upgrade
|
| Book Value Per Share | 0.55 | 0.78 | 0.98 | 0.07 | 0.35 | Upgrade
|
| Tangible Book Value | 6.42 | 8.87 | 11.23 | 0.57 | 2.56 | Upgrade
|
| Tangible Book Value Per Share | 0.54 | 0.77 | 0.97 | 0.07 | 0.34 | Upgrade
|
| Land | 0.61 | 0.59 | 0.37 | 0.39 | 0.42 | Upgrade
|
| Buildings | 2.05 | 1.99 | 1.06 | 1.1 | 1.13 | Upgrade
|
| Machinery | 2.54 | 1.84 | 1.54 | 1.57 | 1.27 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.